Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy

Tissue Antigens

Volumn 57, Issue 6, 2001, Pages 508-519

  Mendez, R ^a   Serrano, A ^a   Jager E ^b   Maleno, I ^a   Ruiz Cabello, F ^a   Knuth, A ^b   Garrido, F ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b KRANKENHAUS NORDWEST   (Germany)

Author keywords

HLA; Immune escape; Loss of heterozygosity; Metastases; Tumor antigen

Indexed keywords

HLA ANTIGEN CLASS 1; HLA B ANTIGEN; PEPTIDE;

AGED; ARTICLE; CASE REPORT; CELL SURFACE; CHROMOSOME 6Q; DISEASE COURSE; FEMALE; HAPLOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; ISOELECTRIC FOCUSING; MELANOMA; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; TANDEM REPEAT;

AGED; ANTIGENS, NEOPLASM; CHROMOSOMES, HUMAN, PAIR 6; FATAL OUTCOME; FEMALE; GENES, MHC CLASS I; HAPLOTYPES; HUMANS; IMMUNOTHERAPY, ACTIVE; LOSS OF HETEROZYGOSITY; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS;

EID: 0034866925     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2001.057006508.x     Document Type: Article

References (33)

1. Natural history of HLA expression during tumour development
2. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
3. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
4. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection
5. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
6. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
7. In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele
8. Beta2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma
9. Mutations of the beta-2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides
10. A simple salting out procedure for extracting DNA from human nucleated cells
11. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens, new tools for genetic analysis
12. Production and characterization of monoclonal antibodies against leukemic cells
13. Evidence for a shared HLA-A intralocus determinant defined by monoclonal antibody 131
14. Stimulation of HLA-A,B,C by IFN-alpha. The derivation of Molt 4 variants and the differential expression of HLA-A,B,C subsets
15. Immunophenotyping of melanomas for tyrosinase: Implications for vaccine development
16. Serological analysis of Melan-A (MART1), a melanocyte-specific protein homogeneously expressed in human melanomas
17. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line
18. Molecular strategies to define HLA haplotype loss in microdissected tumor cells
19. Dinucleotide repeat polymorphisms at the D11S419 and CD3D loci
20. The 1993-94 Genethon human genetic linkage map
21. Characterization of a gastric tumor cell line defective in MHC class I inducibility by both α- and γ-interferon
22. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
23. Immune selection after antigen-specific immunotherapy of melanoma
24. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
25. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
26. Impediments to successful immunotherapy
27. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
28. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions
29. Sequential steps in hematogeneous metastasis cancer cells studied by in vivo videomicroscopy
30. Disseminated tumor cells: Diagnosis, prognostic relevance, phenotyping and therapeutic strategies
31. Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants
32. Heterogeneous HLA-A and HLA-B expression in melanoma metastasis
33. HLA class I antigens in human tumors